Silexion Therapeutics Initiates GMP Manufacturing for SIL204, Secures New Clinical Trial Approval

summarizeSummary

Silexion Therapeutics announced the start of GMP manufacturing for its lead drug candidate, SIL204, and received ethics committee approval for its Phase 2/3 clinical trial, marking significant progress towards patient dosing.

check_boxKey Events

• GMP Manufacturing Initiated

  Silexion Therapeutics has begun Good Manufacturing Practice (GMP) clinical batch manufacturing of SIL204, its siRNA therapy for KRAS-driven cancers, with Catalent in France. This is for the upcoming Phase 2/3 clinical trial in locally advanced pancreatic cancer.

• Clinical Site Approval Secured

  The Helsinki Ethics Committee of Tel Aviv Sourasky Medical Center has approved the planned Phase 2/3 trial of SIL204 at its site, a leading Israeli oncology center, marking a key clinical site activation milestone.

• Advancing Clinical Readiness

  These milestones follow recent Israeli Ministry of Health approval and CTA submission in Germany, materially advancing the company's preparedness for first patient dosing in the Phase 2/3 trial.

auto_awesomeAnalysis

This filing provides critical positive updates for Silexion Therapeutics, a company that recently disclosed a "going concern" warning and secured shareholder approval for a significant capital raise. The initiation of GMP manufacturing for SIL204 means the company is producing clinical-grade drug supply, a necessary step before human trials. Concurrently, securing ethics committee approval from a major Israeli medical center for the Phase 2/3 trial further de-risks the clinical pathway and moves the company closer to enrolling its first patients. These operational and regulatory advancements are vital for the company's ability to execute its core drug development strategy and address its financial challenges.